Alnylam Pharmaceuticals (ALNY)
(Real Time Quote from BATS)
$144.88 USD
+1.17 (0.81%)
Updated Apr 26, 2024 01:51 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
Brokerage Reports
0 items in cart
Alnylam Pharmaceuticals, Inc. [ALNY]
Reports for Purchase
Showing records 101 - 120 ( 406 total )
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Multi-Blockbuster Potential Compounds Vutrisiran and ALN-AGT Continue to Impress; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Focus on P5x25 Strategy Should Drive Substantial Shareholder Value; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q20 Results Reflect Strong Execution That We Expect to Continue in 2021; Upping PT to $235
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Strong Start to the New Year With Positive HELIOS-A Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Glomerular Disorders 101: A Deep Dive Primer On Glomerular Dysfunction
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
To Bleed or Not To Bleed, That Is the $40B Question for Novel Hem-B Nonfactor Replacement Treatments
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
RNAi Peak Productivity Leads to Third RNAi Therapeutic Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Strong Momentum Ahead of Potential Banner Year in 2021
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department